Mashkov O A, Mazur L I, Popov A V, Sorokin B A, Prokhorov Iu S
Ter Arkh. 1991;63(10):138-41.
The new antiprotease hemosorbent Ovosorb was tested during the performance of blood perfusion (BP) used as part of multimodality treatment of 11 patients. Of these, 2 presented with disseminated psoriasis, 3 with arthropathic psoriasis, 1 with psoriatic erythrodermia, 4 with atopic dermatitis, and 1 with recurrent urticaria. BP with the use of the hemosorbent Ovosorb produced the highest effect in patients with atopic dermatitis, psoriatic erythrodermia and recurrent urticaria; BP with Ovosorb was less effective in disseminated psoriasis. The clinical effect was lacking in patients with arthropathic psoriasis. Ovosorb possesses remarkable detoxifying properties, good blood compatibility; it does not provoke any complications in patients with different forms of psoriasis, atopic dermatitis, and urticaria.
新型抗蛋白酶血液吸附剂Ovosorb在11例患者的多模式治疗中作为血液灌注（BP）的一部分进行了测试。其中，2例为泛发性银屑病，3例为关节病型银屑病，1例为银屑病红皮病，4例为特应性皮炎，1例为复发性荨麻疹。使用血液吸附剂Ovosorb进行血液灌注在特应性皮炎、银屑病红皮病和复发性荨麻疹患者中产生了最高的疗效；在泛发性银屑病中，使用Ovosorb进行血液灌注的效果较差。关节病型银屑病患者未出现临床疗效。Ovosorb具有显著的解毒特性、良好的血液相容性；在不同类型的银屑病、特应性皮炎和荨麻疹患者中不会引发任何并发症。
